Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novartis Profits Dip as Generic Rival Challenges Cancer Drug

By Drug Discovery Trends Editor | April 22, 2016

lucarista / Shutterstock.comSwiss pharmaceuticals maker Novartis said net income from continued operations fell 13 percent in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines.

The Basel-based company said Thursday that net income from continuing operations declined to $2.01 billion from $2.31 billion a year earlier. Sales dipped 3 percent to $11.6 billion.

Novartis noted the start of sales of a U.S. generic version of Gleevec – which had cost around $10,000 per month – in February. The company said its core operating margin fell because of the generic competition as well as investments in new product launches and a growth plan for its Alcon eye-care business.

Shares of Novartis were down 0.7 percent at 74.55 Swiss francs in mid-morning trading on the Six Swiss stock exchange.

The company reported net income fell 85 percent from $13 billion last year, which included the impact of a shake-up in its business with an acquisition of oncology and consumer health-care assets from GSK and the divestment of its vaccines and animal health businesses.

The company predicted revenues and core operating income this year would be “broadly in line” with those of 2015, and expects a rise in generic drugs to weigh on its sales by up to $3.2 billion this year, $1 billion more than in the previous year.

Novartis SA, whose group companies employ some 118,000 people worldwide, chalked up net sales of nearly $50 billion and spent nearly $9 billion on research and development in 2015.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50